Health Technology Assessment in Nuclear Medicine

IBA will host an expert webinar on the growing role of Health Technology Assessment (HTA) in nuclear medicine. As radiopharmaceuticals, theranostics, imaging biomarkers, and radionuclide therapies continue to evolve, HTA is becoming a key element in demonstrating clinical value, supporting reimbursement decisions, and enabling broader patient access.

This upcoming session will bring together academic and industry perspectives to discuss how evidence generation, health-economic considerations, and market-access strategies can help position nuclear medicine innovations within the changing European healthcare landscape.